Extended Data Table 2 Area under the curve of change from baseline to weeks 2 and 4 in daily rTNSS

From: Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial

  1. aThe endpoints were analyzed using the Analysis of Covariance (ANCOVA) model, with the baseline daily rTNSS, study site, and treatment group as covariates. Difference in LS means and the corresponding 95%CI were calculated. P values were two-sided and nominal, without adjustments for multiple comparisons. All the data of a.m. and p.m. rTNSS in the 4 weeks of treatment were collected and thus no missing data handling issue for rTNSS. rTNSS, reflective total nasal symptom score; LS, least-squares; s.e.m., standard error of the mean; CI, confidence interval.
  2. Source data
Back to article page